ClinicalTrials.gg
SuspendedNCT05620342Updated Oct 28, 2026

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

An Early Phase 1 interventional study of iC9.GD2.CAR.IL-15 T Infusion in Lung Cancer, Small Cell Lung Carcinoma and Non Small Cell Lung Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Early Phase 1, Interventional, and Treatment

How we know

Why this study was suspended
interim analysis
Updated Oct 28, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Lung Neoplasms by UNC Lineberger Comprehensive Cancer Center — 5 open to participants now, 5 under way, none of them phase 3. Lung Neoplasms · UNC Lineberger Comprehensive Cancer Center.

Planned enrollment
14th of 21
24 · median 38
Started
2023
with 1 other
Phase 1
2 of 26
none open now
Registered
20th of 26
by date

Among the 26 studies in Lung Neoplasms by UNC Lineberger Comprehensive Cancer Center, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 20th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

5 of the 26 studies in Lung Neoplasms by UNC Lineberger Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by UNC Lineberger Comprehensive Cancer Center, or all of them as a file.
02

Study summary

This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.CAR.IL-15 T cells) in subjects with lung cancer. How much (dose) of the iC9-GD2.CAR.IL-15 T cells are safe to use without causing too many side effects and what is the maximum dose that could be tolerated will be studied.

Modified immune cells as an experimental treatment that combines antibodies and T cells will be used. Antibodies are proteins that protect the body from foreign invaders like bacteria. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill viruses and other cells, including tumor cells. Although antibodies and T cells have been used to treat cancer and they both have shown promise, neither alone has been able to cure most patients. This study will combine T cells and antibodies to create a more effective treatment.

The treatment that is being researched in this study is called autologous T lymphocyte chimeric antigen receptor cells targeted against the disialoganglioside (GD2) antigen that expresses Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9). The short name for this treatment is iC9.GD2.CAR.IL-15 T cells therapy is an experimental therapy and has not been approved by the Food and Drug Administration. There are two steps. In the first step, blood will be collected from the subjects to prepare the iC9-GD2.CAR.IL-15 T cells. T cells will be isolated from the blood and modified to make iC9-GD2.CAR.IL-15. In the second step, the iC9-GD2.CAR.IL-15 T cells produced from the subject's own blood will be administered to the subject.

03

Conditions studied

  • Lung Cancer
  • Small Cell Lung Carcinoma
  • Non Small Cell Lung Cancer

Keywords

  • cellular therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to undergo cell procurement explained to, understood by, and signed by the subject.
  2. Subject has a of ≥ 12 weeks.
  3. Subject must be platinum- and either currently receiving or has previously received a PD1/PDL1 inhibitor
  4. Use of systemic at doses ≥10 mg prednisone daily or it's equivalent; those receiving \<10 mg daily may be enrolled at the discretion of the investigator.
  5. Female subjects of must have a negative serum pregnancy test within 72 hours prior to cell procurement.
  6. Subject has demonstrated adequate organ function.

Exclusion criteria

Exclusion Criteria:

1 . Subject has less than 12 weeks of .

2. Subject did not receive platinum-based chemotherapy

3. Subject does not have adequate organ function.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    iC9.GD2.CAR.IL-15 T Therapy

    Experimental: Single Arm Subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy will receive iC9.GD2.CAR.IL-15 T cells were manufactured from their collected blood sample.

    Biological: iC9.GD2.CAR.IL-15 T Infusion

Interventions

  • BiologicaliC9.GD2.CAR.IL-15 T Infusion

    iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse event

    The number of participants with adverse events (AE)s will be reported as a measure of the safety and tolerability of C9.GD2.CAR.IL-15 T. AEs will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

    Time frame: Up to 4 weeks

  2. Cytokine Release Syndrome (CRS)

    CRS will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade 1 - Mild (Symptomatic Management): Fever ≥38\^ o C, No hypotension, No hypoxia, Grade 2 - Moderate (Moderate Intervention): Fever ≥38\^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe (Aggressive Intervention): Fever ≥ 38\^ o C , Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (\>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening (Life-sustaining intervention): Fever ≥38\^oC, Hypotension requiring multiple vasopressors (excluding vasopressin), Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death: Death.

    Time frame: Up to 4 weeks

  3. Neurotoxicity

    Neurotoxicity will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Immune effector cell-associated neurotoxicity syndrome (ICANS) Consensus Grading criteria. ICANS grading criteria are outlined in the protocol on a scale from 1 (mild) to 4 (critical) based on the Immune Effector Cell-Associated Encephalopathy (ICE) Score. Grade 1:Score: 7-9 (mild impairment), Grade 2:Score: 3-6 (moderate impairment), Grade 3: Score: 0-2 (severe impairment), Grade 4: Score: Subject in critical condition, and/or obtunded and cannot perform an assessment of tasks.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Identification of Recommended phase 2 dose (RP2D)

    The RP2D of iC9-GD2.CAR.IL-15 T-cells will be determined based on the modified 3+3 dose-finding rule based on the protocol. Dose escalation will be performed considering the dose-limiting toxicities (DLTs), dose level (DL) will be increased unless there is no DLT.

    Time frame: Up to 4 weeks

  2. Overall Response Rate (ORR)

    ORR will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) which defines Complete Response (CR) as the disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Overall Response Rate (ORR) = number of subjects who achieved CR + number of subjects who achieved PR / total number of subjects who received the study treatment.

    Time frame: Up to 4 weeks

  3. Progression Free Survival (PFS)

    PFS will be measured from the first day of lymphodepletion chemotherapy prior to iC9-GD2.CAR.IL-15 T-cell infusion to progression based on RECIST 1.1 criteria or death. RECIST 1.1 Criteria: Stable Disease (SD): No response or less response than Partial or Progressive and Progressive Disease (PD): A 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 2 years

  4. Overall Survival (OS)

    OS will be measured from the first day of lymphodepletion chemotherapy prior to iC9-GD2.CAR.IL-15 T-cell infusion to date of death for any cause.

    Time frame: Up to 2 years

  5. Duration of Response (DOR)

    DOR is defined as the time from documentation of partial response or response to disease progression based on RECIST 1.1. RECIST 1.1 Criteria: Complete Response (CR) as the disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Overall Response Rate (ORR) = number of subjects who achieved CR + number of subjects who achieved PR / total number of subjects who received the study treatment.Stable Disease (SD): No response or less response than Partial or Progressive and Progressive Disease (PD): A 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 2 years

  6. Duration of Benefit

    Duration of benefit is defined as the time from the first day of lymphodepletion chemotherapy prior to iC9-GD2.CAR.IL-15 T-cell infusion to disease progression, next therapy, or death. RECIST 1.1 Criteria Progressive Disease (PD): A 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 2 years

  7. Disialoganglioside (GD2) Expression

    GD2 Expression will be measured via immunohistochemistry (IHC) on tumor samples collected from subjects.

    Time frame: Baseline

  8. Disialoganglioside Expression and tumor response rate correlations

    GD2 value and tumor response rate graded according to RECIST 1.1 relation will be evaluated.

    Time frame: Up to 2 years

07

Study locations

1 site
  • Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27514, United States
08

References and documents

Publications

  • Ouyang W, Xu Z, Guan S, Hu Y, Gou X, Liu Z, Guo W, Huang Y, Zhang L, Zhang X, Li T, Yang B. Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. Int J Biol Sci. 2025 Jan 20;21(3):1322-1341. doi: 10.7150/ijbs.105973. eCollection 2025. PubMed 39897044 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Nov 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 17, 2022
StartActual
Jun 21, 2023
Primary completionEst.
Nov 24, 2027
CompletionEst.
Oct 24, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended interim analysis
changed Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Suspended
    Why stopped interim analysis
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05620342
Collaborators
Bellicum Pharmaceuticals, United States Department of Defense, M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Jun 21, 2023
Primary completion
Nov 24, 2027 (estimated)
Completion
Oct 24, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Jared Weiss
principal investigator · jared_weiss@med.unc.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion